A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Exclusion Criteria

• •1. Stage IV (metastatic) breast cancer;
• •2. supraclavicular lymph node metastasis；
• •3. For this disease, chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. have been received;
• •4. The patient has a second primary malignancy other than adequately treated skin cancer;
• •5. The patient has undergone major surgical procedures not related to breast cancer within 4 weeks prior to enrollment, or the patient has not fully recovered from such surgical procedures;
• •6. The patient has severe heart disease or discomfort, including but not limited to the following:Diagnosed history of heart failure or systolic dysfunction (LVEF \< 50%)；High-risk uncontrolled arrhythmias；Angina pectoris requiring antianginal medication；Clinically significant heart valve disease；ECG showing transmural myocardial infarction；Poorly controlled high blood pressure；
• •7. Because the patient has other serious and uncontrollable medical diseases, the investigator believes that chemotherapy is contraindicated;
• •8. Known history of allergy to the drug components of this regimen; history of immunodeficiency, including HIV positive test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;